Hospital
Valley Medical Facilities INC
Valley Medical Facilities INC was paid $4.22M by Medicaid between Jan 2018 and Dec 2024, across 173 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoVALLEY MEDICAL FACILITIES INC
SEWICKLEY, PA 15143
SEWICKLEY, PA 15143
33aNPI1588770416assigned 08/22/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.22M
24GClaims137,432
24DCodes billed173
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#69 of 154
Median peer was paid$2.82M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 223 | $11K | |
| 2019 | 306 | $8K | |
| 2020 | 14,218 | $346K | |
| 2021 | 80,292 | $2.11M | |
| 2022 | 17,453 | $645K | |
| 2023 | 17,236 | $771K | |
| 2024incomplete | 7,704 | $331K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 13,420 | 12,004 | $1.42M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 9,017 | 8,033 | $661K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.9% | 3,202 | 2,924 | $420K |
| G0378 | Hospital observation service, per hour | 4.7% | 754 | 347 | $199K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 785 | 763 | $141K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.7% | 1,308 | 1,241 | $114K |
| 80053 | Comprehensive metabolic panel | 2.5% | 9,626 | 9,113 | $104K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.3% | 3,516 | 3,357 | $95K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.6% | 1,757 | 525 | $68K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.3% | 573 | 570 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 9,954 | 9,423 | $55K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.2% | 1,510 | 1,479 | $50K |
161 more codes
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 241 | $48K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 712 | $40K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 945 | $37K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,184 | $32K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 377 | $31K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,600 | $28K |
| 80050 | General health panel | <1% | 526 | $27K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,081 | $26K |
| 80061 | Lipid panel | <1% | 1,705 | $26K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,688 | $23K |
| 84703 | <1% | 2,077 | $20K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,484 | $20K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 433 | $18K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 71 | $18K |
| 93971 | <1% | 271 | $16K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 446 | $14K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 281 | $14K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 428 | $12K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 323 | $12K |
| 76830 | Ultrasound, transvaginal | <1% | 240 | $11K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 791 | $11K |
| 84484 | <1% | 1,393 | $10K | |
| 81003 | <1% | 3,460 | $10K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 153 | $10K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 160 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 829 | $10K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 104 | $9K |
| 83690 | <1% | 1,927 | $9K | |
| 83735 | <1% | 1,466 | $9K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,119 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,043 | $7K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 445 | $7K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 322 | $7K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 322 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 167 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 907 | $7K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 500 | $6K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 265 | $6K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,853 | $6K |
| 85027 | <1% | 986 | $6K | |
| 95886 | <1% | 106 | $6K | |
| 83880 | <1% | 219 | $6K | |
| 73610 | <1% | 288 | $6K | |
| 84439 | <1% | 592 | $5K | |
| X0621 | <1% | 35 | $5K | |
| 85730 | <1% | 925 | $5K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 644 | $5K |
| 76536 | <1% | 90 | $5K | |
| 88342 | <1% | 115 | $5K | |
| 83605 | <1% | 711 | $5K | |
| 86803 | <1% | 231 | $5K | |
| 84702 | <1% | 278 | $5K | |
| 86318 | <1% | 225 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 26 | $4K |
| 72100 | <1% | 219 | $4K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 64 | $4K |
| 73630 | <1% | 358 | $4K | |
| 82607 | <1% | 321 | $4K | |
| 87040 | <1% | 248 | $4K | |
| 73030 | <1% | 247 | $4K | |
| 76801 | <1% | 85 | $4K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 14 | $4K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 43 | $4K |
| 86780 | <1% | 225 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 15 | $4K |
| 85610 | <1% | 1,153 | $4K | |
| 82803 | <1% | 179 | $4K | |
| 90837 | Psychotherapy session, about an hour | <1% | 72 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,329 | $3K |
| 71250 | <1% | 54 | $3K | |
| 76775 | <1% | 70 | $3K | |
| 73560 | <1% | 209 | $3K | |
| 85378 | <1% | 318 | $3K | |
| 73130 | <1% | 259 | $3K | |
| 86850 | <1% | 411 | $3K | |
| 80076 | <1% | 310 | $3K | |
| 86702 | <1% | 221 | $3K | |
| 97161 | <1% | 86 | $3K | |
| 10060 | <1% | 25 | $2K | |
| 86701 | <1% | 221 | $2K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 81 | $2K |
| 87340 | <1% | 146 | $2K | |
| 84145 | <1% | 131 | $2K | |
| 87390 | <1% | 221 | $2K | |
| 82728 | <1% | 178 | $2K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 34 | $2K |
| 74018 | <1% | 165 | $2K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 84 | $2K |
| 70486 | <1% | 28 | $2K | |
| 86901 | <1% | 471 | $2K | |
| 86900 | <1% | 471 | $2K | |
| 82043 | <1% | 202 | $2K | |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 127 | $2K |
| 73110 | <1% | 133 | $1K | |
| 93970 | <1% | 25 | $1K | |
| 73502 | <1% | 74 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 44 | $1K |
| 87186 | <1% | 201 | $1K | |
| 86618 | <1% | 53 | $1K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 29 | $1K |
| 95909 | <1% | 13 | $1K | |
| 84153 | <1% | 42 | $1K | |
| 82550 | <1% | 153 | $1K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 670 | $999.90 |
| 85651 | <1% | 331 | $990.91 | |
| 96376 | <1% | 241 | $983.20 | |
| 90715 | <1% | 108 | $790.72 | |
| 86762 | <1% | 37 | $773.37 | |
| 86140 | <1% | 225 | $673.03 | |
| 74019 | <1% | 42 | $635.29 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,042 | $621.25 |
| 83550 | <1% | 111 | $557.88 | |
| 86038 | <1% | 37 | $556.11 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,321 | $514.96 |
| 82570 | <1% | 61 | $464.40 | |
| 73080 | <1% | 38 | $450.80 | |
| 82746 | <1% | 38 | $414.46 | |
| 82962 | <1% | 369 | $374.42 | |
| 87077 | <1% | 54 | $326.55 | |
| 82077 | <1% | 201 | $322.73 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 338 | $248.48 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,142 | $219.19 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,388 | $208.90 |
| 72040 | <1% | 14 | $199.95 | |
| 73590 | <1% | 12 | $186.45 | |
| 82784 | <1% | 13 | $149.08 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12 | $148.42 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 652 | $141.27 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 477 | $139.48 |
| J2704 | Injection, propofol, 10 mg | <1% | 588 | $138.26 |
| 76937 | <1% | 13 | $98.40 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 14 | $87.57 |
| 84100 | <1% | 15 | $85.83 | |
| 87070 | <1% | 12 | $67.62 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 27 | $65.97 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 80 | $63.00 |
| J3490 | Unclassified drugs | <1% | 35 | $55.05 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 586 | $52.60 |
| 87081 | <1% | 13 | $50.60 | |
| 83516 | <1% | 28 | $49.60 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 86 | $42.91 |
| 85018 | <1% | 15 | $40.55 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 188 | $38.48 |
| 88304 | <1% | 28 | $29.20 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 150 | $24.16 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 123 | $23.71 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 16 | $14.96 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 17 | $13.70 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 448 | $13.15 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 31 | $5.44 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 40 | $4.70 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 12 | $1.41 |
| 3050F | 0% | 406 | $0.00 | |
| 3051F | 0% | 12 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 73 | $0.00 |
| 3044F | 0% | 577 | $0.00 | |
| 3048F | 0% | 650 | $0.00 | |
| 3049F | 0% | 466 | $0.00 | |
| 3011F | 0% | 1,522 | $0.00 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 51 | $0.00 |
| 3061F | 0% | 42 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSENBERGER, ROBERT (CFO)
| Provider | Location | Paid |
|---|---|---|
| Adena Health System | Chillicothe, OH | $98.12M |
| Valley Medical Facilities, INC. | Sewickley, PA | $19.37M |
| Valley Medical Facilities INC | Beaver, PA | $10.29M |
| Valley Medical Facilities, INC. | Sewickley, PA | $3.71M |
| Valley Medical Facilities, INC. | Mc Kees Rocks, PA | $1.86M |
| Valley Medical Facilities INC | Mc Kees Rocks, PA | $80K |
| Valley Medical Facilities, INC. | Wexford, PA | $32K |
| Valley Medical Facilities, INC. | Bellevue, PA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.